Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019

• Published in: Critical care medicine Vol. 48; no. 9; p. e783
• Main Authors: Maatman, Thomas K, Jalali, Farid, Feizpour, Cyrus, Douglas, 2nd, Anthony, McGuire, Sean P, Kinnaman, Gabriel, Hartwell, Jennifer L, Maatman, Benjamin T, Kreutz, Rolf P, Kapoor, Rajat, Rahman, Omar, Zyromski, Nicholas J, Meagher, Ashley D
• Format: Journal Article
• Language: English
• Published: United States 01.09.2020
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants - therapeutic use; Betacoronavirus; Biomarkers - blood; Comorbidity; Coronavirus Infections - complications; Coronavirus Infections - drug therapy; Coronavirus Infections - mortality; COVID-19; Critical Illness; Female; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Pneumonia, Viral - complications; Pneumonia, Viral - drug therapy; Pneumonia, Viral - mortality; SARS-CoV-2; Thrombelastography; Thrombophilia - diagnosis; Thrombophilia - drug therapy; Thrombophilia - etiology; Venous Thromboembolism - epidemiology; Venous Thromboembolism - etiology; Venous Thromboembolism - prevention & control; Young Adult
• ISSN: 1530-0293
• DOI: 10.1097/CCM.0000000000004466

The aim of this study was to determine the frequency of venous thromboembolism in critically ill coronavirus disease 2019 patients and associate a degree of inflammatory marker elevation to venous thromboembolism development. An observational study that identified patients with severe coronavirus disease 2019 between March 12, 2020, and March 31, 2020. Data reported are those available through May 6, 2020. A multicenter study including three Indianapolis area academic hospitals. Two-hundred forty consecutive patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were admitted to one of three hospitals. One-hundred nine critically ill coronavirus disease 2019 patients admitted to the ICU were included in the analysis. All patients received routine subcutaneous chemical venous thromboembolism prophylaxis. The primary outcome of this study was to determine the frequency of venous thromboembolism and the degree of inflammatory and coagulation marker elevation associated with venous thromboembolism development. Descriptive statistics outlined the frequency of venous thromboembolism at any time during severe coronavirus disease 2019. Clinical course and laboratory metrics were compared between patients that developed venous thromboembolism and patients that did not develop venous thromboembolism. Hypercoagulable thromboelastography was defined as two or more hypercoagulable parameters. One-hundred nine patients developed severe coronavirus disease 2019 requiring ICU care. The mean (± SD) age was 61 ± 16 years and 57% were male. Seventy-five patients (69%) were discharged home, 7 patients (6%) remain in the hospital, and 27 patients (25%) died. Venous thromboembolism was diagnosed in 31 patients (28%) 8 ± 7 days after hospital admission, including two patients diagnosed with venous thromboembolism at presentation to the hospital. Elevated admission D-dimer and peak D-dimer were associated with venous thromboembolism development (p < 0.05). D-dimer greater than 2,600 ng/mL predicted venous thromboembolism with an area under the receiver operating characteristic curve of 0.760 (95% CI, 0.661-0.858; p < 0.0001), sensitivity of 89.7%, and specificity of 59.5%. Twelve patients (11%) had thromboelastography performed and 58% of these patients had a hypercoagulable study. The calculated coagulation index was hypercoagulable in 50% of patients with thromboelastography. These data show that coronavirus disease 2019 results in a hypercoagulable state. Routine chemical venous thromboembolism prophylaxis may be inadequate in preventing venous thromboembolism in severe coronavirus disease 2019.